ASH 2021 -- cytopenic myelofibrosis

[EPguy]

I've been checking out the Hematology conference. For cytopenic myelofibrosis a Phase 3 trial PERSIST-2 reports pacritinib has advantages over Rux.

cancernetwork.com/view/trea...

<<Among the 43 patients included in the efficacy analysis who received pacritinib, 28% had a reported reduction in spleen volume compared with 11% among patients who received ruxolitinib (n = 9)... Modified total symptom score response was reported in 37% vs 11%, respectively>>

<<those in the ruxolitinib arm had a higher rate of grade 3 or higher infection at 17% compared with 11% among those in the pacritinib arm>>

<<Fatal adverse effects were also higher among those in the ruxolitinib arm (25%) compared with the pacritinib arm (7%>>

FDA decision date is February 28, 2022

That fatal stat looks not so good, but more details about it would be helpful. Overall seems there are clear benefits.